Evidence map›Paper›PMID 33932848›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2021

Evaluation of SARS-CoV-2 total antibody detection via a lateral flow nanoparticle fluorescence immunoassay.

Mamdouh Sibai, Daniel Solis, Katharina Röltgen, Bryan A Stevens, Kenji O Mfuh, Malaya K Sahoo, Run Z Shi, James Zehnder, Scott D Boyd, Benjamin A Pinsky

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mamdouh SibaiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Daniel SolisDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Katharina RöltgenDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Bryan A StevensDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA.
Kenji O MfuhClinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA.
Malaya K SahooDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Run Z ShiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
James ZehnderDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Scott D BoydDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, USA.
Benjamin A PinskyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA; Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: bpinsky@stanford.edu.

Funding

Project 3: T CellsU54CA260517 · NCI · STANFORD UNIVERSITY · PI BOYD, SCOTT DEXTER · 2020 to 2024
$10.4M
Effects of aging on primary and secondary vaccine responses in a 15-year longitudinal cohortR01AI130398 · NIAID · STANFORD UNIVERSITY · PI BOYD, SCOTT DEXTER · 2017 to 2021
$4.0M
Storage and recall of human B cell memory of influenza over tissues and timeR01AI127877 · NIAID · STANFORD UNIVERSITY · PI BOYD, SCOTT DEXTER · 2017 to 2021
$2.0M
NCI NIH HHS U54 CA260517NIAID NIH HHS R01 AI127877NIAID NIH HHS R01 AI130398
6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) endgame may benefit from simple, accurate antibody testing to characterize seroprevalence and immunization coverage.

objectivesTo evaluate the performance of the lateral flow QIAreach anti-SARS-CoV-2 Total rapid nanoparticle fluorescence immunoassay compared to reference isotype-specific IgG, IgM, and IgA SARS-CoV-2 ELISA using S1 or receptor binding domain (RBD) as antigens. STUDY

designA diagnostic comparison study was carried out using 154 well-characterized heparin plasma samples. Agreement between assays was assessed by overall, positive, and negative percent agreement and Cohen's kappa coefficient.

resultsOverall agreement between the QIAreach anti-SARS-CoV-2 Total and any anti-spike domain (S1 or RBD) antibody isotype was 96.0 % (95 % CI 89.8-98.8), the positive percent agreement was 97.6 % (95 % CI 91.0-99.9), the negative percent agreement was 88.2 % (95 % CI 64.4-98.0). The kappa coefficient was 0.86 (95 % CI 0.72 to 0.99).

conclusionThe QIAreach anti-SARS-CoV-2 Total rapid antibody test provides comparable performance to high-complexity, laboratory-based ELISA.

Indexed as

AdultAgedAntibodies, ViralCOVID-19Enzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueHumansMaleMiddle AgedNanoparticlesSARS-CoV-2Antibodies, ViralRapid lateral flow immunoassaySARS-CoV-2Serology

Identifiers

PMID33932848
PMCPMC8015349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.